AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

UCB

Major Shareholding Notification Oct 9, 2025

4017_mrq_2025-10-09_b9f96c7e-0419-4f14-8a28-aeac0952a270.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Transparency notification FMR LLC

Brussels (Belgium), 9 October 2025 – 20:00 (CEST)Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 7 October 2025.

FMR LLC., notified that, following an acquisition of UCB shares with voting rights by controlled undertakings of FMR LLC, the aggregate holding of FMR LLC crossed upwards a 7.5% threshold on 6 October 2025.

On 6 October 2025, FMR LLC. (taking into account the holding of its affiliates) owned 14,655,548 UCB shares with voting rights, representing 7.53% of the total number of shares issued by the company (194,505,658), versus 6.86% (13,351,678 UCB shares) in the previous notification dated 5 August 2025.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
Name Address (for legal entities)
FMR LLC The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County,
Delaware, 19801.

Date on which the threshold is crossed: 6 October 2025.

Threshold crossed (in %): 7.5%.

Denominator: 194,505,658.

UCB News

Notified details

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the securities Linked to securities Not linked to the securities
FMR LLC 0 0 0
FIAM LLC 2,066,532 2,192,023 1.13%
Fidelity Management & Research Company LLC 9,799,506 10,891,049 5.60%
Fidelity Management Trust
Company
802,024 915,986 0.47%
Fidelity Institutional Asset
Management Trust Company
466,173 460,673 0.24%
FMR Investment
Management (UK) Limited
216,621 194,738 0.10%
Strategic Advisers LLC 822 1,080 0.00%
Subtotal 13,351,678 14,655,548 7.53%
TOTAL 14,655,548 0 7.53% 0.00%
B) Equivalent financial instruments After the transaction
Holders of equivalent financial instruments Type of financial instrument Expiration
date
Exercise
period or
date
# of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement
TOTAL 0 0.00%

TOTAL (A & B) # of voting
rights
% of voting rights
CALCULATE 14,655,548 7.53%

Chain of controlled undertakings through which the holding is effectively held

FIAM LLC and Fidelity Institutional Asset Management Trust Company are controlled by FIAM Holdings LLC.

FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC.

Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC.

Fidelity Management Trust Company is controlled by FMTC Holdings LLC.

FIAM Holdings LLC, Fidelity Management & Research Company LLC, FMTC Holdings LLC, Fidelity Advisory Holdings LLC are controlled by FMR LLC.

FMR LLC is not a controlled undertaking.

Additional information

The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations

Antje Witte

T +32 2 559 94 14

[email protected]

Corporate Communications

Laurent Schots

T+32 2 559 92 64

[email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).

Talk to a Data Expert

Have a question? We'll get back to you promptly.